Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

January 11th 2021

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Frontline CLL Treatment: Addressing Unmet Needs

January 8th 2021

Allogeneic Transplantation for CLL

January 8th 2021

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

January 8th 2021

BTK Monotherapy for Frontline CLL

January 8th 2021

Selecting Frontline Therapy to Treat CLL

January 8th 2021

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

January 7th 2021

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma

January 7th 2021

January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CML

January 7th 2021

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic myeloid leukemia.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 6th 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review

January 4th 2021

January 4, 2021 - The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.